These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

285 related items for PubMed ID: 11720181

  • 1. Systemic sclerosis-related Raynaud's phenomenon: effects of iloprost infusion therapy on serum cytokine, growth factor and soluble adhesion molecule levels.
    Mittag M, Beckheinrich P, Haustein UF.
    Acta Derm Venereol; 2001; 81(4):294-7. PubMed ID: 11720181
    [Abstract] [Full Text] [Related]

  • 2. Prostacyclin analogue iloprost influences endothelial cell-associated soluble adhesion molecules and growth factors in patients with systemic sclerosis: a time course study of serum concentrations.
    Rehberger P, Beckheinrich-Mrowka P, Haustein UF, Sticherling M.
    Acta Derm Venereol; 2009; 89(3):245-9. PubMed ID: 19479119
    [Abstract] [Full Text] [Related]

  • 3. Soluble adhesion molecules (ICAM-1, VCAM-1, and E-selectin) and vascular endothelial growth factor (VEGF) in patients with distinct variants of rheumatoid synovitis.
    Klimiuk PA, Sierakowski S, Latosiewicz R, Cylwik JP, Cylwik B, Skowronski J, Chwiecko J.
    Ann Rheum Dis; 2002 Sep; 61(9):804-9. PubMed ID: 12176805
    [Abstract] [Full Text] [Related]

  • 4. Decrease in circulating endothelial cell adhesion molecule and thrombomodulin levels during oral iloprost treatment in rheumatoid arthritis patients: preliminary results.
    Boehme MW, Gao IK, Norden C, Lemmel EM.
    Rheumatol Int; 2006 Feb; 26(4):340-7. PubMed ID: 15700117
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. [Effects of long-term iloprost therapy on Raynaud's phenomenon in progressive systemic sclerosis].
    Cordioli E, Virgilio S, Ghirardi R, Martinelli M.
    Minerva Med; 1992 Nov; 83(11):739-44. PubMed ID: 1281297
    [Abstract] [Full Text] [Related]

  • 7. Measurement of soluble adhesion molecules in primary Raynaud's phenomenon and in Raynaud's phenomenon secondary to connective tissue diseases.
    Brevetti G, De Caterina M, Martone VD, Corrado S, Silvestro A, Spadaro G, Scopacasa F.
    Int J Clin Lab Res; 2000 Nov; 30(2):75-81. PubMed ID: 11043500
    [Abstract] [Full Text] [Related]

  • 8. Soluble adhesion molecules (sVCAM-1, sE-selectin), vascular endothelial growth factor (VEGF) and endothelin-1 in patients with systemic sclerosis: relationship to organ systemic involvement.
    Kuryliszyn-Moskal A, Klimiuk PA, Sierakowski S.
    Clin Rheumatol; 2005 Apr; 24(2):111-6. PubMed ID: 15349798
    [Abstract] [Full Text] [Related]

  • 9. Antioxidant status after iloprost treatment in patients with Raynaud's phenomenon secondary to systemic sclerosis.
    Balbir-Gurman A, Braun-Moscovici Y, Livshitz V, Schapira D, Markovits D, Rozin A, Boikaner T, Nahir AM.
    Clin Rheumatol; 2007 Sep; 26(9):1517-21. PubMed ID: 17401513
    [Abstract] [Full Text] [Related]

  • 10. Reduction of soluble adhesion molecules (sICAM-1, sVCAM-1, and sE-selectin) and vascular endothelial growth factor levels in serum of rheumatoid arthritis patients following multiple intravenous infusions of infliximab.
    Klimiuk PA, Sierakowski S, Domysławska I, Fiedorczyk M, Chwiećko J.
    Arch Immunol Ther Exp (Warsz); 2004 Sep; 52(1):36-42. PubMed ID: 15053231
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Correlation between increased nitric oxide production and markers of endothelial activation in systemic sclerosis: findings with the soluble adhesion molecules E-selectin, intercellular adhesion molecule 1, and vascular cell adhesion molecule 1.
    Andersen GN, Caidahl K, Kazzam E, Petersson AS, Waldenström A, Mincheva-Nilsson L, Rantapää-Dahlqvist S.
    Arthritis Rheum; 2000 May; 43(5):1085-93. PubMed ID: 10817563
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Serial circulating adhesion molecule levels reflect disease severity in systemic sclerosis.
    Denton CP, Bickerstaff MC, Shiwen X, Carulli MT, Haskard DO, Dubois RM, Black CM.
    Br J Rheumatol; 1995 Nov; 34(11):1048-54. PubMed ID: 8542206
    [Abstract] [Full Text] [Related]

  • 16. Long-term beneficial effects of statins on vascular manifestations in patients with systemic sclerosis.
    Kuwana M, Okazaki Y, Kaburaki J.
    Mod Rheumatol; 2009 Nov; 19(5):530-5. PubMed ID: 19590932
    [Abstract] [Full Text] [Related]

  • 17. Long-term low molecular weight heparin therapy for severe Raynaud's phenomenon: a pilot study.
    Denton CP, Howell K, Stratton RJ, Black CM.
    Clin Exp Rheumatol; 2000 Nov; 18(4):499-502. PubMed ID: 10949727
    [Abstract] [Full Text] [Related]

  • 18. Treatment of ischaemic digital ulcers and prevention of gangrene with intravenous iloprost in systemic sclerosis.
    Zachariae H, Halkier-Sørensen L, Bjerring P, Heickendorff L.
    Acta Derm Venereol; 1996 May; 76(3):236-8. PubMed ID: 8800308
    [Abstract] [Full Text] [Related]

  • 19. Oral iloprost in Raynaud's phenomenon secondary to systemic sclerosis: a multicentre, placebo-controlled, dose-comparison study.
    Black CM, Halkier-Sørensen L, Belch JJ, Ullman S, Madhok R, Smit AJ, Banga JD, Watson HR.
    Br J Rheumatol; 1998 Sep; 37(9):952-60. PubMed ID: 9783759
    [Abstract] [Full Text] [Related]

  • 20. Infusion of iloprost, a prostacyclin analogue, for treatment of Raynaud's phenomenon in systemic sclerosis.
    McHugh NJ, Csuka M, Watson H, Belcher G, Amadi A, Ring EF, Black CM, Maddison PJ.
    Ann Rheum Dis; 1988 Jan; 47(1):43-7. PubMed ID: 2449871
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.